CPL Biologicals (CPLB), a JV of Ahmedabad based Cadila Pharmaceuticals and US
based Novavax Inc has completed construction of its vaccine facility at Dholka
near Ahmedabad in Gujarat.
The facility set up at an investment of about Rs 100 crore can produce up to
60 million doses of vaccines per annum. Currently, the facility is undergoing
the validation process. It is expected to begin the production on getting
permission from Food and Drug Administration, Gujarat and Drug Controller
General of India.
Further, CPLB plans to produce seasonal and pandemic flu vaccines based on
Novavax's advanced virus-like particle (VLP) technology which enables the rapid
development and production of novel vaccines without the use of live virus.
Vaccine against flu is likely to be the first product to be launched.